Dashboard
Manage Tickers

APLS


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

what-analysts-are-saying-about-apellis-pharmaceuticals-stock
What Analysts Are Saying About Apellis Pha...
06/28/2024 20:02:39

baird-maintains-outperform-on-apellis-pharmaceuticals-maintains-100-price-target
Baird Maintains Outperform on Apellis Phar...
06/28/2024 17:10:19

Baird analyst Colleen Kusy maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Outperform and maintains $100 price target.

nike-accolade-and-other-big-stocks-moving-lower-in-fridays-pre-market-session
Nike, Accolade And Other Big Stocks Moving...
06/28/2024 13:08:43

apellis-committee-says-it-plans-to-seek-re-examination-following-negative-chmp-opinion-for-pegcetacoplan-for-geographic-atrophy-in-the-eu
Apellis Committee Says It Plans To Seek Re...
06/28/2024 11:01:10

piper-sandler-initiates-coverage-on-apellis-pharmaceuticals-with-neutral-rating-announces-price-target-of-46
Piper Sandler Initiates Coverage On Apelli...
05/31/2024 09:55:14

Piper Sandler analyst Biren Amin initiates coverage on Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral rating and annou...

expert-outlook-apellis-pharmaceuticals-through-the-eyes-of-15-analysts
Expert Outlook: Apellis Pharmaceuticals Th...
05/28/2024 14:00:27

hc-wainwright--co-reiterates-buy-on-apellis-pharmaceuticals-maintains-92-price-target
HC Wainwright & Co. Reiterates Buy on Apel...
05/28/2024 10:31:22

HC Wainwright & Co. analyst Douglas Tsao reiterates Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $92 p...

apellis-pharmaceuticals-and-sobi-announce-positive-one-year-results-from-phase-2-noble-study-of-pegcetacoplan-for-post-transplant-recurrence-of-c3-glomerulopathy-c3g-and-ic-mpgn
Apellis Pharmaceuticals And Sobi Announce ...
05/24/2024 14:01:58

Rapid reduction in disease activity seen at 12 weeks was sustained at one year55% of patients showed zero C3c staining intensit...

wells-fargo-maintains-equal-weight-on-apellis-pharmaceuticals-lowers-price-target-to-48
Wells Fargo Maintains Equal-Weight on Apel...
05/23/2024 14:27:27

Wells Fargo analyst Derek Archila maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Equal-Weight and lowers the price t...

apellis-pharmaceuticals-refinances-existing-debt-with-up-to-475m-non-dilutive-credit-facility
Apellis Pharmaceuticals Refinances Existin...
05/14/2024 12:30:09

Apellis received $375 million in funding at close, with ability to access an additional $100 millionMajority of initial proceed...

citigroup-maintains-buy-on-apellis-pharmaceuticals-lowers-price-target-to-60
Citigroup Maintains Buy on Apellis Pharmac...
05/08/2024 19:34:29

Citigroup analyst Yigal Nochomovitz maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target f...

hc-wainwright--co-reiterates-buy-on-apellis-pharmaceuticals-maintains-92-price-target
HC Wainwright & Co. Reiterates Buy on Apel...
05/08/2024 19:08:49

HC Wainwright & Co. analyst Douglas Tsao reiterates Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $92 p...

in-depth-examination-of-14-analyst-recommendations-for-apellis-pharmaceuticals
In-Depth Examination Of 14 Analyst Recomme...
05/08/2024 18:00:15

ubs-maintains-buy-on-apellis-pharmaceuticals-lowers-price-target-to-85
UBS Maintains Buy on Apellis Pharmaceutica...
05/08/2024 13:14:20

UBS analyst Eliana Merle maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target from $89 to ...

needham-reiterates-buy-on-apellis-pharmaceuticals-maintains-85-price-target
Needham Reiterates Buy on Apellis Pharmace...
05/08/2024 09:45:19

Needham analyst Joseph Stringer reiterates Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $85 price target.

apellis-pharmaceuticals-q1-eps-054-misses-053-estimate-sales-17232m-beat-16335m-estimate
Apellis Pharmaceuticals Q1 EPS $(0.54) Mis...
05/07/2024 11:10:34

Apellis Pharmaceuticals (NASDAQ:APLS) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimat...

mizuho-maintains-neutral-on-apellis-pharmaceuticals-lowers-price-target-to-52
Mizuho Maintains Neutral on Apellis Pharma...
04/29/2024 11:34:46

Mizuho analyst Graig Suvannavejh maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral and lowers the price target ...

hc-wainwright--co-reiterates-buy-on-apellis-pharmaceuticals-maintains-92-price-target
HC Wainwright & Co. Reiterates Buy on Apel...
04/26/2024 18:22:23

HC Wainwright & Co. analyst Douglas Tsao reiterates Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $92 p...

european-medicines-agency-has-reset-the-review-of-apellis-pharmaceuticals-intravitreal-pegcetacoplan-for-geographic-atrophy-to-the-last-phase-of-the-initial-assessment-day-180-apellis-anticipates-an-opinion-from-chmp-no-later-than-july-2024
European Medicines Agency Has Reset The Re...
04/26/2024 11:19:34

needham-reiterates-buy-on-apellis-pharmaceuticals-maintains-85-price-target
Needham Reiterates Buy on Apellis Pharmace...
04/25/2024 17:15:07

Needham analyst Joseph Stringer reiterates Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $85 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)
07/16/2024 Teladoc Health, Inc. (TDOC)
07/16/2024 Vestis Corporation (VSTS)
07/22/2024 Cambium Networks Corporation (CMBM)
07/22/2024 Biogen Inc. (BIIB)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)